Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference

MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21^st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET.

Access to this event will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT^® technology. PRINT enabled the development of YUTREPIA^® (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Chief Business Officer
919.328.4350
[email protected]

Media:
[email protected]

You May Also Be Interested In

• Steward Group Launches New Independent Portfolio Management Firm in Partnership with Purpose Advisor Solutions
• Want Your Own Barrel of Bourbon? BarrelPick.com Launches at Kentucky Bourbon Festival
• AJ Auto Expands Specialist Jaguar Land Rover Key Replacement Services for Drivers Facing Lost, Damaged and Replacement Key Problems